Bumetanide
بومتانید
❤️ Cardiovascular SystemLoop diuretic
Market / country: 🇺🇸 USA
Bumex (US)
🧮 Dose calculator
Edema · Regimen source: FDA Bumetanide · Dosage and Administration
- • If inadequate, a 2nd or 3rd dose at 4–5 h intervals up to 10 mg/day. For chronic oedema alternate-day or 3–4 days on, 1–2 days off is safest. About 1 mg bumetanide ≈ 40 mg furosemide. FDA Bumetanide · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Anuria; hepatic coma; severe electrolyte depletion until corrected; hypersensitivity. FDA Bumetanide · Contraindications
Formulations
- 0.5 mg tablet — tablet 🇺🇸 USA FDA Bumetanide · How Supplied
- 1 mg tablet — tablet 🇺🇸 USA FDA Bumetanide · How Supplied
- 2 mg tablet — tablet 🇺🇸 USA FDA Bumetanide · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Bumetanide · Pregnancy
“Teratogenic Effects Bumetanide is neither teratogenic nor embryocidal in mice when given in doses up to 3400 times the maximum human therapeutic dose.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Bumetanide · Nursing Mothers
“As a general rule, nursing should not be undertaken while the patient is on bumetanide since it may be excreted in human milk.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Bumetanide · Pediatric Use
“Safety and effectiveness in pediatric patients below the age of 18 have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Bumetanide · Geriatric Use
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA213942
- DailyMed (FDA label)FDA Bumetanide
- MedlinePlus (NIH)BumetanideBumetanide Nasal Spray
- WHO ATC/DDDC03CA02
- Darooyab (Iran)Bumetanide
🇮🇷 Registered in Iran Darooyab · G-1569/Bumetanide
Dosage forms with Iranian generic codes, per Darooyab.
- 10070 · BUMETANIDE 1MG TAB · قرص بومتانید ۱ میلیگرم
- 06629 · BUMETANIDE 5MG TAB · قرص بومتانید ۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Bumetanide · How SuppliedFDA Bumetanide · Dosage and AdministrationFDA Bumetanide · ContraindicationsFDA Bumetanide · PregnancyFDA Bumetanide · Nursing MothersFDA Bumetanide · Pediatric UseFDA Bumetanide · Geriatric UseFDA Bumetanide · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1569/Bumetanide
- Clinical review⚠ Unverified